A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2022-07-25
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-12-06 (study day 115); relationship: N
mild
assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-01-05 (study day 510); relationship: N
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-04-03 (study day 599); relationship: not assessed
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-04-05 (study day 601); relationship: N
Data queries
No data queries.